
<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://proteopedia.org/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Pierre-Yves+Mocaer</id>
	<title>Proteopedia - User contributions [en]</title>
	<link rel="self" type="application/atom+xml" href="https://proteopedia.org/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Pierre-Yves+Mocaer"/>
	<link rel="alternate" type="text/html" href="https://proteopedia.org/Special:Contributions/Pierre-Yves_Mocaer"/>
	<updated>2026-09-25T08:53:29Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885509</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885509"/>
		<updated>2014-01-09T19:49:15Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN OF HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a variant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which the team has characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helices (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheets (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helices, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
A lot of empty structures are present between helices.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bond&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each monomere is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other one. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as Valine, Isoleucine, and nonpolar sections as Histadine, Methionine, and Glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonds between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt; Thr188 O Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N.&lt;br /&gt;
On each monomer, a hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilizes the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a hydrogen bond located at the end of helix 3 which permit inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cl-&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain: cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt; (copper (II) ions) with high affinity: [http://en.wikipedia.org/wiki/Cadmium &#039;&#039;&#039;Cd2+&#039;&#039;&#039;] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; . Moreover, the entire protein can bind a Cu2+ ion on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational changes&#039;&#039;&#039; with a lot of unknown effects. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). &lt;br /&gt;
For this domain, two [http://en.wikipedia.org/wiki/Glycosylation glycosylated sites] exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly alpha-helical protein to an aggregated form, which is substantially &#039;&#039;&#039;enriched in beta-sheet.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
The substitution by a Valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent &#039;&#039;&#039;steric troubles&#039;&#039;&#039; between them. In some cases of variants, the beta-sheet interface is&#039;&#039;&#039; entirely absent&#039;&#039;&#039;. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally &#039;&#039;&#039;influences the aggregation form&#039;&#039;&#039; and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the prion protein influences disease.&lt;br /&gt;
For example, Valine 129 is finding on CJD whereas methionine 129 is finding in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can appears in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can have an effect on mental disease and is finding in CJD. In the same way, a subtitution of Asparagine 171 in Serine 171 can be find in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.rcsb.org/pdb/explore.do?structureId=3HAF EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885508</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885508"/>
		<updated>2014-01-09T19:48:00Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN OF HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a variant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which the team has characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helices (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheets (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helices, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
A lot of empty structures are present between helices.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bond&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each monomere is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other one. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as Valine, Isoleucine, and nonpolar sections as Histadine, Methionine, and Glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonds between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt; Thr188 O Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N.&lt;br /&gt;
On each monomer, a hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilizes the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a hydrogen bond located at the end of helix 3 which permit inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cl-&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain: cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt; (copper (II) ions) with high affinity: [http://en.wikipedia.org/wiki/Cadmium &#039;&#039;&#039;Cd2+&#039;&#039;&#039;] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; . Moreover, the entire protein can bind a Cu2+ ion on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational changes&#039;&#039;&#039; with a lot of unknown effects. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1).&lt;br /&gt;
For this domain, two [http://en.wikipedia.org/wiki/Glycosylation glycosylated sites] exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly alpha-helical protein to an aggregated form, which is substantially &#039;&#039;&#039;enriched in beta-sheet.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
The substitution by a Valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent &#039;&#039;&#039;steric troubles&#039;&#039;&#039; between them. In some cases of variants, the beta-sheet interface is&#039;&#039;&#039; entirely absent&#039;&#039;&#039;. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally &#039;&#039;&#039;influences the aggregation form&#039;&#039;&#039; and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the prion protein influences disease.&lt;br /&gt;
For example, Valine 129 is finding on CJD whereas methionine 129 is finding in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can appears in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can have an effect on mental disease and is finding in CJD. In the same way, a subtitution of Asparagine 171 in Serine 171 can be find in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.rcsb.org/pdb/explore.do?structureId=3HAF EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885486</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885486"/>
		<updated>2014-01-09T18:03:03Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory diseases, such as lung and skin inflammatory diseases, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the alpha helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grants an invasive phenotype to cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT-3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Contributors==&lt;br /&gt;
&lt;br /&gt;
Tristan Butaye and Vincent Saravaki&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885485</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885485"/>
		<updated>2014-01-09T18:01:42Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory diseases, such as lung and skin inflammatory diseases, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the alpha helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grants an invasive phenotype to cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Contributors==&lt;br /&gt;
&lt;br /&gt;
Tristan Butaye and Vincent Saravaki&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885483</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885483"/>
		<updated>2014-01-09T18:00:23Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory diseases, such as lung and skin inflammatory diseases, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the alpha helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grants an invasive phenotype to cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Contributors==&lt;br /&gt;
&lt;br /&gt;
Tristan Butaye and Vincent Saravaki&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885482</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885482"/>
		<updated>2014-01-09T17:58:01Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory diseases, such as lung and skin inflammatory diseases, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the alpha helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Contributors==&lt;br /&gt;
&lt;br /&gt;
Tristan Butaye and Vincent Saravaki&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885479</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885479"/>
		<updated>2014-01-09T17:55:20Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory diseases, such as lung and skin inflammatory diseases, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Contributors==&lt;br /&gt;
&lt;br /&gt;
Tristan Butaye and Vincent Saravaki&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885478</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885478"/>
		<updated>2014-01-09T17:55:06Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory diseases, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Contributors==&lt;br /&gt;
&lt;br /&gt;
Tristan Butaye and Vincent Saravaki&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885477</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885477"/>
		<updated>2014-01-09T17:54:30Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Contributors==&lt;br /&gt;
&lt;br /&gt;
Tristan Butaye and Vincent Saravaki&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885475</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885475"/>
		<updated>2014-01-09T17:48:01Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which the team has characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helices (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheets (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helices, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
A lot of empty structures are present between helices.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bond&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as Valine, Isoleucine, and nonpolar sections as Histadine, Methionine, and Glutamic acid.&lt;br /&gt;
It occurs  hydrogen bond between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt; Thr188 O Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N.&lt;br /&gt;
On each monomer, a hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilizes the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a hydrogen bond located at the end of helix 3 which permit inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cl-&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain: cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt; (copper (II) ions) with high affinity: [http://en.wikipedia.org/wiki/Cadmium &#039;&#039;&#039;Cd2+&#039;&#039;&#039;] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; . Moreover, the entire protein can bind a Cu2+ ion on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational changes&#039;&#039;&#039; with a lot of unknown effects. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1).&lt;br /&gt;
For this domain, two [http://en.wikipedia.org/wiki/Glycosylation glycosylated sites] exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly alpha-helical protein to an aggregated form, which is substantially &#039;&#039;&#039;enriched in beta-sheet.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
The substitution by a Valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent &#039;&#039;&#039;steric troubles&#039;&#039;&#039; between them. In some cases of variants, the beta-sheet interface is&#039;&#039;&#039; entirely absent&#039;&#039;&#039;. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally &#039;&#039;&#039;influences the aggregation form&#039;&#039;&#039; and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the prion protein influences disease.&lt;br /&gt;
For example, Valine 129 is finding on CJD whereas methionine 129 is finding in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can appears in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can have an effect on mental disease and is finding in CJD. In the same way, a subtitution of Asparagine 171 in Serine 171 can be find in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.rcsb.org/pdb/explore.do?structureId=3HAF EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885474</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885474"/>
		<updated>2014-01-09T17:46:04Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Contributors==&lt;br /&gt;
&lt;br /&gt;
Tristan Butaye and Vincent Saravaki&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885473</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885473"/>
		<updated>2014-01-09T17:43:53Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which the team has characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helices (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheets (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helices, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
A lot of empty structures are present between helices.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bond&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as Valine, Isoleucine, and nonpolar sections as Histadine, Methionine, and Glutamic acid.&lt;br /&gt;
It occurs  hydrogen bond between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt; Thr188 O Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N.&lt;br /&gt;
On each monomer, a hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilizes the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a hydrogen bond located at the end of helix 3 which permit inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain: cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt; (copper (II) ions) with high affinity: [http://en.wikipedia.org/wiki/Cadmium &#039;&#039;&#039;Cd2+&#039;&#039;&#039;] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; . Moreover, the entire protein can bind a Cu2+ ion on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational changes&#039;&#039;&#039; with a lot of unknown effects. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1).&lt;br /&gt;
For this domain, two [http://en.wikipedia.org/wiki/Glycosylation glycosylated sites] exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly alpha-helical protein to an aggregated form, which is substantially &#039;&#039;&#039;enriched in beta-sheet.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
The substitution by a Valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent &#039;&#039;&#039;steric troubles&#039;&#039;&#039; between them. In some cases of variants, the beta-sheet interface is&#039;&#039;&#039; entirely absent&#039;&#039;&#039;. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally &#039;&#039;&#039;influences the aggregation form&#039;&#039;&#039; and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the prion protein influences disease.&lt;br /&gt;
For example, Valine 129 is finding on CJD whereas methionine 129 is finding in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can appears in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can have an effect on mental disease and is finding in CJD. In the same way, a subtitution of Asparagine 171 in Serine 171 can be find in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.rcsb.org/pdb/explore.do?structureId=3HAF EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885471</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885471"/>
		<updated>2014-01-09T17:36:49Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which the team has characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helices (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheets (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helices, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
A lot of empty structures are present between helices.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bond&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as Valine, Isoleucine, and nonpolar sections as Histadine, Methionine, and Glutamic acid.&lt;br /&gt;
It occurs  hydrogen bond between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt; Thr188 O Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N.&lt;br /&gt;
On each monomer, a hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilizes the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a hydrogen bond located at the end of helix 3 which permit inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain: cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt; (copper (II) ions) with high affinity: [http://en.wikipedia.org/wiki/Cadmium &#039;&#039;&#039;Cd2+&#039;&#039;&#039;] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; . Moreover, the entire protein can bind a Cu2+ ion on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational changes&#039;&#039;&#039; with a lot of unknown effects. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1).&lt;br /&gt;
For this domain, two [http://en.wikipedia.org/wiki/Glycosylation glycosylated sites] exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly alpha-helical protein to an aggregated form, which is substantially &#039;&#039;&#039;enriched in beta-sheet.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
The substitution by a Valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent &#039;&#039;&#039;steric troubles&#039;&#039;&#039; between them. In some cases of variants, the beta-sheet interface is&#039;&#039;&#039; entirely absent&#039;&#039;&#039;. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally &#039;&#039;&#039;influences the aggregation form&#039;&#039;&#039; and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the prion protein influences disease.&lt;br /&gt;
For example, Valine 129 is finding on CJD whereas methionine 129 is finding in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can appears in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can have an effect on mental disease and is finding in CJD. In the same way, a subtitution of Asparagine 171 in Serine 171 can be find in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbsum/3haf EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885470</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885470"/>
		<updated>2014-01-09T17:35:49Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which the team has characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helices (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheets (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helices, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
A lot of empty structures are present between helices.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bond&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as Valine, Isoleucine, and nonpolar sections as Histadine, Methionine, and Glutamic acid.&lt;br /&gt;
It occurs  hydrogen bond between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt; Thr188 O Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N.&lt;br /&gt;
On each monomer, a hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilizes the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a hydrogen bond located at the end of helix 3 which permit inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain: cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt; (copper (II) ions) with high affinity: [http://en.wikipedia.org/wiki/Cadmium &#039;&#039;&#039;Cd2+&#039;&#039;&#039;] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; . Moreover, the entire protein can bind a Cu2+ ion on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational changes&#039;&#039;&#039; with a lot of unknown effects. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1).&lt;br /&gt;
For this domain, two [http://en.wikipedia.org/wiki/Glycosylation glycosylated sites] exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly alpha-helical protein to an aggregated form, which is substantially &#039;&#039;&#039;enriched in beta-sheet.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
The substitution by a Valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent &#039;&#039;&#039;steric troubles&#039;&#039;&#039; between them. In some cases of variants, the beta-sheet interface is&#039;&#039;&#039; entirely absent&#039;&#039;&#039;. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally &#039;&#039;&#039;influences the aggregation form&#039;&#039;&#039; and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the prion protein influences disease.&lt;br /&gt;
For example, Valine 129 is finding on CJD whereas methionine 129 is finding in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can appears in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can have an effect on mental disease and is finding in CJD. In the same way, a subtitution of Asparagine 171 in Serine 171 can be find in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbsum/3haf EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885469</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885469"/>
		<updated>2014-01-09T17:34:54Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which the team has characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helices (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheets (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helices, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
A lot of empty structures are present between helices.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bond&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as Valine, Isoleucine, and nonpolar sections as Histadine, Methionine, and Glutamic acid.&lt;br /&gt;
It occurs  hydrogen bond between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt; Thr188 O −Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N.&lt;br /&gt;
On each monomer, a hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilizes the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a hydrogen bond located at the end of helix 3 which permit inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain: cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt; (copper (II) ions) with high affinity: [http://en.wikipedia.org/wiki/Cadmium &#039;&#039;&#039;Cd2+&#039;&#039;&#039;] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; . Moreover, the entire protein can bind a Cu2+ ion on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational changes&#039;&#039;&#039; with a lot of unknown effects. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1).&lt;br /&gt;
For this domain, two [http://en.wikipedia.org/wiki/Glycosylation glycosylated sites] exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly alpha-helical protein to an aggregated form, which is substantially &#039;&#039;&#039;enriched in beta-sheet.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
The substitution by a Valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent &#039;&#039;&#039;steric troubles&#039;&#039;&#039; between them. In some cases of variants, the beta-sheet interface is&#039;&#039;&#039; entirely absent&#039;&#039;&#039;. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally &#039;&#039;&#039;influences the aggregation form&#039;&#039;&#039; and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the prion protein influences disease.&lt;br /&gt;
For example, Valine 129 is finding on CJD whereas methionine 129 is finding in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can appears in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can have an effect on mental disease and is finding in CJD. In the same way, a subtitution of Asparagine 171 in Serine 171 can be find in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbsum/3haf EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885468</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885468"/>
		<updated>2014-01-09T17:31:22Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885467</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885467"/>
		<updated>2014-01-09T17:27:03Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282.&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D. These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885465</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885465"/>
		<updated>2014-01-09T17:26:13Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885464</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885464"/>
		<updated>2014-01-09T17:24:38Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which the team has characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helices (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheets (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helices, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
A lot of empty structures are present between helices.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bond&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as Valine, Isoleucine, and nonpolar sections as Histadine, Methionine, and Glutamic acid.&lt;br /&gt;
It occurs  hydrogen bond between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt; Thr188 O −Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N.&lt;br /&gt;
On each monomer, a hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilizes the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a hydrogen bond located at the end of helix 3 which permit inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain: cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt; (copper (II) ions) with high affinity: [http://en.wikipedia.org/wiki/Cadmium &#039;&#039;&#039;Cd2+&#039;&#039;&#039;] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; . Moreover, the entire protein can bind a Cu2+ ion on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational changes&#039;&#039;&#039; with a lot of unknown effects. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1).&lt;br /&gt;
For this domain, two [http://en.wikipedia.org/wiki/Glycosylation glycosylated sites] exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbsum/3haf EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885463</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885463"/>
		<updated>2014-01-09T17:22:22Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: &amp;lt;scene name=&#039;56/568028/Site3_oncostatin/1&#039;&amp;gt;Phe160 and Lys163&amp;lt;/scene&amp;gt;, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Osm interact osmr.png|frame|left|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; Complementarity between the interaction surfaces of hOSM and gp130.The solvent-accessible surfaces of site 2 on hOSM (left) and the cognate binding site on gp130 (right) are displayed with areas contributed by residues implicated in binding highlighted as coloured patches.]] [[Image:Oncostatin site3.jpg|frame|center|&#039;&#039;&#039;Fig.3&#039;&#039;&#039; Site 3 configuration with residues for OSMR and LIFR binding in red.]]&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.4&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885461</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885461"/>
		<updated>2014-01-09T17:19:00Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which the team has characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helices (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheets (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helices, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helices.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bond&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as Valine, Isoleucine, and nonpolar sections as Histadine, Methionine, and Glutamic acid.&lt;br /&gt;
It occurs  hydrogen bond between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt; Thr188 O −Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N.&lt;br /&gt;
On each monomer, a hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilizes the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a hydrogen bond located at the end of helix 3 which permit inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbsum/3haf EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885460</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885460"/>
		<updated>2014-01-09T17:18:05Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and Cys167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Asn124 and Gly120&amp;lt;/scene&amp;gt; which are situated in helix C. Two other residues contribute to the linking: &amp;lt;scene name=&#039;56/568028/Residues_binding_to_gp130/1&#039;&amp;gt;Gln16 and Gln20&amp;lt;/scene&amp;gt;, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: Phe160 and Lys163, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Osm interact osmr.png|frame|left|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; Complementarity between the interaction surfaces of hOSM and gp130.The solvent-accessible surfaces of site 2 on hOSM (left) and the cognate binding site on gp130 (right) are displayed with areas contributed by residues implicated in binding highlighted as coloured patches.]] [[Image:Oncostatin site3.jpg|frame|center|&#039;&#039;&#039;Fig.3&#039;&#039;&#039; Site 3 configuration with residues for OSMR and LIFR binding in red.]]&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.4&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885458</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885458"/>
		<updated>2014-01-09T17:12:10Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and 167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt;helix between residues Ala95 and Asp97 followed by the alpha helix up to Ser101&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are Asn124 and Gly120 which are situated in helix C. Two other residues contribute to binding the linking: Gln16 and Gln20, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: Phe160 and Lys163, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Osm interact osmr.png|frame|left|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; Complementarity between the interaction surfaces of hOSM and gp130.The solvent-accessible surfaces of site 2 on hOSM (left) and the cognate binding site on gp130 (right) are displayed with areas contributed by residues implicated in binding highlighted as coloured patches.]] [[Image:Oncostatin site3.jpg|frame|center|&#039;&#039;&#039;Fig.3&#039;&#039;&#039; Site 3 configuration with residues for OSMR and LIFR binding in red.]]&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.4&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885457</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885457"/>
		<updated>2014-01-09T17:07:41Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfolded proteins induces the death of cells and the accumulation of [http://en.wikipedia.org/wiki/Amyloid amyloid plaques] in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer major protein prion] going from residue 90 to 231. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, which influence the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbsum/3haf EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885456</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885456"/>
		<updated>2014-01-09T17:07:16Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and 167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are &amp;lt;scene name=&#039;56/568028/Bcloops_helixes/1&#039;&amp;gt; 310 helix between residues Ala95 and Asp97 followed by the α helix up to Ser101&amp;lt;/scene&amp;gt;a. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are Asn124 and Gly120 which are situated in helix C. Two other residues contribute to binding the linking: Gln16 and Gln20, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: Phe160 and Lys163, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Osm interact osmr.png|frame|left|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; Complementarity between the interaction surfaces of hOSM and gp130.The solvent-accessible surfaces of site 2 on hOSM (left) and the cognate binding site on gp130 (right) are displayed with areas contributed by residues implicated in binding highlighted as coloured patches.]] [[Image:Oncostatin site3.jpg|frame|center|&#039;&#039;&#039;Fig.3&#039;&#039;&#039; Site 3 configuration with residues for OSMR and LIFR binding in red.]]&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.4&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885455</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885455"/>
		<updated>2014-01-09T16:58:28Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and 167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of &amp;lt;scene name=&#039;56/568028/Abloop_residues/1&#039;&amp;gt;two α-helices from Pro43 to Arg46 and Glu59 to Gly64&amp;lt;/scene&amp;gt;, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 310 helix between residues Ala95 and Asp97 followed by the α helix up to Ser101. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are Asn124 and Gly120 which are situated in helix C. Two other residues contribute to binding the linking: Gln16 and Gln20, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: Phe160 and Lys163, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Osm interact osmr.png|frame|left|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; Complementarity between the interaction surfaces of hOSM and gp130.The solvent-accessible surfaces of site 2 on hOSM (left) and the cognate binding site on gp130 (right) are displayed with areas contributed by residues implicated in binding highlighted as coloured patches.]] [[Image:Oncostatin site3.jpg|frame|center|&#039;&#039;&#039;Fig.3&#039;&#039;&#039; Site 3 configuration with residues for OSMR and LIFR binding in red.]]&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.4&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885454</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885454"/>
		<updated>2014-01-09T16:54:56Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
*[http://proteopedia.org/wiki/index.php/3haf Proteopedia prion]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbsum/3haf EBISum]&lt;br /&gt;
&lt;br /&gt;
=References=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885453</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885453"/>
		<updated>2014-01-09T16:51:48Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. &amp;lt;scene name=&#039;56/568028/Oncostatine_bridge2/1&#039;&amp;gt;The second disulphide bridge between Cys49 and 167&amp;lt;/scene&amp;gt; links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of two α-helices from Pro43 to Arg46 and Glu59 to Gly64, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 310 helix between residues Ala95 and Asp97 followed by the α helix up to Ser101. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are Asn124 and Gly120 which are situated in helix C. Two other residues contribute to binding the linking: Gln16 and Gln20, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: Phe160 and Lys163, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Osm interact osmr.png|frame|left|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; Complementarity between the interaction surfaces of hOSM and gp130.The solvent-accessible surfaces of site 2 on hOSM (left) and the cognate binding site on gp130 (right) are displayed with areas contributed by residues implicated in binding highlighted as coloured patches.]] [[Image:Oncostatin site3.jpg|frame|center|&#039;&#039;&#039;Fig.3&#039;&#039;&#039; Site 3 configuration with residues for OSMR and LIFR binding in red.]]&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.4&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885452</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885452"/>
		<updated>2014-01-09T16:51:28Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:17661791&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
* http://www.ebi.ac.uk/pdbsum/3haf&lt;br /&gt;
* http://proteopedia.org/wiki/index.php/3haf&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885451</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885451"/>
		<updated>2014-01-09T16:49:06Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
* http://www.ebi.ac.uk/pdbsum/3haf&lt;br /&gt;
* http://proteopedia.org/wiki/index.php/3haf&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885450</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885450"/>
		<updated>2014-01-09T16:47:12Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN IN HUMAN PRION: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885448</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885448"/>
		<updated>2014-01-09T16:46:06Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;br /&gt;
&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=3HAF DOMAIN: Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain in Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885447</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885447"/>
		<updated>2014-01-09T16:45:47Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name=&#039;56/568028/Oncostatin_bridge1/1&#039;&amp;gt;The disulphide bridge between Cys6 and Cys127&amp;lt;/scene&amp;gt; connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. The second disulphide bridge between Cys49 and 167 links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of two α-helices from Pro43 to Arg46 and Glu59 to Gly64, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 310 helix between residues Ala95 and Asp97 followed by the α helix up to Ser101. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are Asn124 and Gly120 which are situated in helix C. Two other residues contribute to binding the linking: Gln16 and Gln20, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: Phe160 and Lys163, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Osm interact osmr.png|frame|left|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; Complementarity between the interaction surfaces of hOSM and gp130.The solvent-accessible surfaces of site 2 on hOSM (left) and the cognate binding site on gp130 (right) are displayed with areas contributed by residues implicated in binding highlighted as coloured patches.]] [[Image:Oncostatin site3.jpg|frame|center|&#039;&#039;&#039;Fig.3&#039;&#039;&#039; Site 3 configuration with residues for OSMR and LIFR binding in red.]]&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.4&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885446</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885446"/>
		<updated>2014-01-09T16:45:26Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&#039;&#039;&#039;3HAF DOMAIN|22|&#039;&#039;&#039;&lt;br /&gt;
&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain in Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885445</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885445"/>
		<updated>2014-01-09T16:44:17Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;=&#039;&#039;&#039;3HAF DOMAIN&#039;&#039;&#039;=&lt;br /&gt;
&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Overview=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain in Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Ligands and Interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|500px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Protreopedia Page Contributors and Editors=&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885444</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885444"/>
		<updated>2014-01-09T16:41:40Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;=&#039;&#039;&#039;3HAF DOMAIN&#039;&#039;&#039;=&lt;br /&gt;
&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&#039;&#039;&#039;=Introduction=&#039;&#039;&#039;&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&#039;&#039;&#039;=Structure of 3HAF domain of Human Prion=&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&#039;&#039;&#039;=Ligand and interactions =&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&#039;&#039;&#039;=Repercussion of the M129/V129 polymorphism =&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|400px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&#039;&#039;&#039;=See Also=&#039;&#039;&#039;&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
&#039;&#039;&#039;=Reference=&#039;&#039;&#039;&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Protreopedia Page Contributors and Editors&#039;&#039;&#039;==&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885443</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885443"/>
		<updated>2014-01-09T16:41:15Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, &amp;lt;scene name=&#039;56/568028/Abloop_helixb_aromatic/1&#039;&amp;gt;except Phe56 (AB loop) and Phe70 (Helix B)&amp;lt;/scene&amp;gt;, highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
The disulphide bridge between Cys6 and Cys127 connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. The second disulphide bridge between Cys49 and 167 links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of two α-helices from Pro43 to Arg46 and Glu59 to Gly64, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 310 helix between residues Ala95 and Asp97 followed by the α helix up to Ser101. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are Asn124 and Gly120 which are situated in helix C. Two other residues contribute to binding the linking: Gln16 and Gln20, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: Phe160 and Lys163, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Osm interact osmr.png|frame|left|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; Complementarity between the interaction surfaces of hOSM and gp130.The solvent-accessible surfaces of site 2 on hOSM (left) and the cognate binding site on gp130 (right) are displayed with areas contributed by residues implicated in binding highlighted as coloured patches.]] [[Image:Oncostatin site3.jpg|frame|center|&#039;&#039;&#039;Fig.3&#039;&#039;&#039; Site 3 configuration with residues for OSMR and LIFR binding in red.]]&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.4&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885442</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885442"/>
		<updated>2014-01-09T16:38:33Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
=3HAf domain=&lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|400px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Protreopedia Page Contributors and Editors&#039;&#039;&#039;==&lt;br /&gt;
&lt;br /&gt;
Pierre-Yves MOCAER and Laurane LEXCELLENT&lt;br /&gt;
&lt;br /&gt;
Student 1A ESBS (Promo 2016)&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885441</id>
		<title>Sandbox Reserved 830</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_830&amp;diff=1885441"/>
		<updated>2014-01-09T16:38:24Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox_Reserved_ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:1evs.png|left|200px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Oncostatin M, also called OSM, is encoded by the OSM gene and it is mostly produced in the end of the activation of macrophages and T cells. OSM belongs to the family of gp130 cytokines implying that it signals through the receptors containing gp130. OSM has been shown to have a lot of pleiotropic functions in cell proliferation, differentiation and inflammatory response. Thus, studies highlight its roles in cancer, bone and liver metabolism alteration, as well as in severe inflammatory disease, such as lung and skin inflammatory disease, atherosclerosis, cardiovascular diseases, and rheumatoid polyarthritis.&lt;br /&gt;
{{STRUCTURE_1evs|  PDB=1evs  |  SCENE=  }} &lt;br /&gt;
===Human Oncostatin M===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Structure==&lt;br /&gt;
OSM is a compact molecule with dimensions of approximately 20 Å x 27 Å x 56 Å, that fit with the up-up-down-down &amp;lt;scene name=&#039;56/568028/Oncostatine_bundle/2&#039;&amp;gt;four-helices bundle&amp;lt;/scene&amp;gt; structure (Fig.1).&lt;br /&gt;
&lt;br /&gt;
[[Image:Oncostatin structure.png|frame|left|&#039;&#039;&#039;Fig.1&#039;&#039;&#039; Ribbon colored diagram of hOSM from N-terminus in blue to the C-terminus in red. The two disulphide bonds are shown as ball-and-sticks models with the sulphur atoms represented as yellow spheres. The CD loop as observed in LIF is represented by the transparent dotted section.]] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM structure is composed of the four main  α helical region (helix A, residues 10–37; helix B, residues 67–90; helix C, residues 105–131; helix  D, residues 159–185) linked by two long overhand loops (AB loop, residues 38–66; CD loop, residues 130–158) and one short loop (BC loop, residues 91–104). Globally, OSM arrangement corresponds to &amp;lt;scene name=&#039;56/568028/Adhelix_parallel_bchelix/1&#039;&amp;gt;A-D forming one pair of helices which is parallel to the B-C pair&amp;lt;/scene&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Helices A and C have breaks in the hydrogen-bonding pattern of their structure, forming tight substitute hydrogen bonds with water molecules. Indeed, it results in a kink in helix A (&amp;lt;scene name=&#039;56/568028/Kink_helixa/1&#039;&amp;gt;and slightly in helix C between residues Gln112 and Pro116&amp;lt;/scene&amp;gt;) induced by a disruption in the helical conformation, due to the Gln25 and Leu30 hydrogen bonds with four water molecules. &amp;lt;scene name=&#039;56/568028/Oncostatin_helix_310/1&#039;&amp;gt;Helix A residues between Thr27 and Ile37&amp;lt;/scene&amp;gt; take on a 3&amp;lt;sub&amp;gt;10&amp;lt;/sub&amp;gt; helix conformation. With this curved structure, helices A and C enhance the compaction of the A-D and B-C parallel helix pairs, causing the core of OSM to be isolated from the solvent. &lt;br /&gt;
&lt;br /&gt;
This core is composed of &amp;lt;scene name=&#039;56/568028/Helixd_aromatic/1&#039;&amp;gt;two aromatic stacking groups&amp;lt;/scene&amp;gt;, Phe56, Tyr173, Phe169 and Phe176 on one hand, and Phe170, Phe185 and Trp187 on the other hand. All these aromatic residues belong to helix D, except Phe56 (AB loop) and Phe70 (Helix B), highlighting the hydrophobicity of helix D. &lt;br /&gt;
&lt;br /&gt;
The disulphide bridge between Cys6 and Cys127 connects the N-terminal loop (Gly4-Glu9) preceding helix A to the C terminus of helix C. The second disulphide bridge between Cys49 and 167 links the start of the AB loop to the N-Terminal region of helix D. &lt;br /&gt;
&lt;br /&gt;
The AB loop is composed of two α-helices from Pro43 to Arg46 and Glu59 to Gly64, while the residues in between pack closely and extensively against helix D. Comparatively, BC and CD loops are less stacking to the core. The BC loop located on the top of the four-helix bundle exhibits an important amount of B factors, along with several more classical secondary structures, which are a 310 helix between residues Ala95 and Asp97 followed by the α helix up to Ser101. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
OSM contains two binding sites for the heterodimer receptor: site 2 and site 3.&lt;br /&gt;
Site 2 of OSM binds to gp130 subunit with four residues located in helices A and C. The most important residues are Asn124 and Gly120 which are situated in helix C. Two other residues contribute to binding the linking: Gln16 and Gln20, located in helix A. OSMR allows binding of OSM on three residues: Tyr196, Phe169 and Glu282 (Fig.2).&lt;br /&gt;
Site 3 of OSM binds to LIFR or OSMR thanks to two residues: Phe160 and Lys163, located in the N-terminal end of helix D (Fig.3). These amino acids are conserved in all cytokines&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 10997905 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Osm interact osmr.png|frame|left|&#039;&#039;&#039;Fig.2&#039;&#039;&#039; Complementarity between the interaction surfaces of hOSM and gp130.The solvent-accessible surfaces of site 2 on hOSM (left) and the cognate binding site on gp130 (right) are displayed with areas contributed by residues implicated in binding highlighted as coloured patches.]] [[Image:Oncostatin site3.jpg|frame|center|&#039;&#039;&#039;Fig.3&#039;&#039;&#039; Site 3 configuration with residues for OSMR and LIFR binding in red.]]&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Functions==&lt;br /&gt;
Oncosatin M binds to two different receptors which are heterodimers:  gp130/LIFRα and OSMRβ/gp130. These receptors are present on a lot of different cell lines.&lt;br /&gt;
Binding of OSM on its receptors activates several signaling pathways like JAK/STAT3, MAP Kinase (MAPK), and PI3′Kinase (PI3′K). The chosen pathway depends on the cell type&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Onco mécha.jpg|center|frame|&#039;&#039;&#039;Fig.4&#039;&#039;&#039; The different pathways in which oncostatin M is involved.]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Activation of those pathways stimulates several responses. The main one is proliferation of a lot of different cell lines by increasing production of molecules, such as proliferation factors and metalloproteinase inhibitors.  In endothelial cells, vascular endothelial growth factors (VEGF) are secreted, promoting angiogenesis. Binding of OSM induces inhibition of other cell proliferation, like stem cells or tumor cells, by blocking the cell cycle in G2/M&amp;lt;ref name=&amp;quot;three&amp;quot;&amp;gt; PMID: 10446061 &amp;lt;/ref&amp;gt;. Binding of OSM grant an invasive phenotype of cells by stimulation of chemokine secretion (like eotaxin). Chemokine allows activation of immune cells as well, and then stimulates the production of antibodies&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. Physiological function of OSM in the central nervous system remains unknown&amp;lt;ref group=&amp;quot;&amp;quot;&amp;gt; PMID: 14985435 &amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Disease==&lt;br /&gt;
Oncostatin M is a pleiotropic protein and it takes part in the regulation of several organ systems. Thus, OSM is involved in a lot of pathologies mainly due to its large signaling functions targeting so many different cell types. OSM impacts cell proliferation and stimulate angiogenesis, thus its alterations greatly increase the risks of tumor growth and cancer development. &lt;br /&gt;
&lt;br /&gt;
Defects in OSM and OSMR impact metastatic melanoma cell lines due to the PKC Δ-dependent phosphorylation of Ser 727 on STAT-3 and other signaling pathways. Moreover some epigenetic mechanisms have been shown to be responsible for altering the nature of metastatic melanoma, increasing OSMR expression and responsiveness of the cells&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
Defects in OMS induce high levels of osteoblasts and osteoblast markers in differentiated osteosarcoma cells dramatically enhancing the proliferation of osteosarcoma cells, while stimulating an invasive phenotypic alteration of these cells mainly by the MMP-2 and VEGF expression, mediated by STAT3. &amp;lt;ref name=&amp;quot;four&amp;quot;&amp;gt; PMID: 12218157 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OSM has been shown to stimulate the proliferation of Ewing sarcoma cell lines, 22Rv1 prostate cancer cells, SKOV3 ovarian cancer cells, while an increase in OSMR expression has been found in cervical carcinoma. &lt;br /&gt;
&lt;br /&gt;
OSMR modifications were found to enhance human lung carcinoma development by reducing the cells’ sensitivity to OSM. &lt;br /&gt;
&lt;br /&gt;
Epigenetic mutations, such as methylation, cause the silencing of OSMR, thus the inhibition of both colon cancer cell lines and papillary thyroid cancer cell proliferation&amp;lt;ref name=&amp;quot;two&amp;quot;&amp;gt; PMID: 24381786 &amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Bravo, J.]]&lt;br /&gt;
[[Category: Deller, M C.]]&lt;br /&gt;
[[Category: Heath, J K.]]&lt;br /&gt;
[[Category: Hudson, K R.]]&lt;br /&gt;
[[Category: Ikemizu, S.]]&lt;br /&gt;
[[Category: Jones, E Y.]]&lt;br /&gt;
[[Category: 4-helix bundle]]&lt;br /&gt;
[[Category: Cytokine]]&lt;br /&gt;
[[Category: Gp130 binding cytokine]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885440</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885440"/>
		<updated>2014-01-09T16:36:58Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
=3HAf domain=&lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|400px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885439</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885439"/>
		<updated>2014-01-09T16:36:22Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
3HAf domain &lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|400px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885438</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885438"/>
		<updated>2014-01-09T16:35:52Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
3HAf domain &lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|400px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885437</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885437"/>
		<updated>2014-01-09T16:35:27Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
3HAf domain &lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|400px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885436</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885436"/>
		<updated>2014-01-09T16:34:40Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
3HAf domain &lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Yes.jpg|left|400px||thumb|&#039;&#039;&#039;Polymorphism of beta sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=File:Yes.jpg&amp;diff=1885435</id>
		<title>File:Yes.jpg</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=File:Yes.jpg&amp;diff=1885435"/>
		<updated>2014-01-09T16:33:32Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885434</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885434"/>
		<updated>2014-01-09T16:33:08Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
3HAf domain &lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:C:\Users\Pierre-Yves\Desktop\yes.jpg]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885432</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885432"/>
		<updated>2014-01-09T16:30:40Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
3HAf domain &lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:C:\Users\Pierre-Yves\Desktop\emboj2009333f3.jpg]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885431</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885431"/>
		<updated>2014-01-09T16:25:09Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
3HAf domain &lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Images.jpg|left|700px||thumb|&#039;&#039;&#039;Polymorphism of β-sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885430</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885430"/>
		<updated>2014-01-09T16:24:34Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
3HAf domain &lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:Images.jpg|left|400px||thumb|&#039;&#039;&#039;Polymorphism of β-sheet interface&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885428</id>
		<title>Sandbox Reserved 815</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox_Reserved_815&amp;diff=1885428"/>
		<updated>2014-01-09T16:21:49Z</updated>

		<summary type="html">&lt;p&gt;Pierre-Yves Mocaer: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;!-- PLEASE DO NOT DELETE THIS TEMPLATE --&amp;gt;&lt;br /&gt;
{{Sandbox-reserved-ESBS}}&lt;br /&gt;
&amp;lt;!-- PLEASE ADD YOUR CONTENT BELOW HERE --&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Image:54.jpg|right|550px|thumb|&#039;&#039;&#039;3HAF Domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
3HAf domain &lt;br /&gt;
&lt;br /&gt;
=Introduction=&lt;br /&gt;
[[Image:3haf bio r 500.jpg|left|220px|thumb|&#039;&#039;&#039;3HAF Domain-Dimer&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Prions, misfolded proteins, are responsible of the transmissible spongiform encephalopathy in mammals. The primitive protein is involved in the cell differentiation and adhesion. In humans, prions cause. In humans, prions cause [http://en.wikipedia.org/wiki/Creutzfeldt%E2%80%93Jakob_disease Creutzfeldt-Jakob Disease](CJD), [http://en.wikipedia.org/wiki/Fatal_familial_insomnia Fatal Familial Insomnia](FFI) and [http://en.wikipedia.org/wiki/Kuru_%28disease%29 kuru].&lt;br /&gt;
&lt;br /&gt;
Human prion is a membrane protein of 16284.86 Da. The infectious agent penetrates the neuron and due to reasons and mechanisms still misunderstood, it multiplies, by opening/folding normal proteins in pathogenic prions. This new form cannot be degraded by proteolysis and the aggregation of misfiled proteins induces the death of cells and the accumulation of amyloid plaque in the brain.&lt;br /&gt;
&lt;br /&gt;
3HAF is a vaiant domain of the major [http://www.proteopedia.org/wiki/index.php/Human_Prion_Protein_Dimer prion]protein going from residue 90 to 231, which is constitute of 253 amino acids. Compare to the sequence of the major prion protein, a Valine substitutes a Methionine at the 129 residue, influencing the susceptibility of the formation of the prion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=Structure of 3HAF domain of Human Prion=&lt;br /&gt;
&lt;br /&gt;
The 3HAF structure results from a work leaded by Lee S. in 2010, in which they have characterized seven variants of the human prion. The structure was determined by XRAY diffraction in a 2.26-Angstrom resolution.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Vjvk.jpg|left|350px||thumb|&#039;&#039;&#039;Structure of 3HAF domain&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Secondary Structure==&lt;br /&gt;
&lt;br /&gt;
The unique chain of 3HAF is constituted of 7 helix (Alpha helix 112-135, Alpha helix 144-153, 3/10 helix 154-156, 3/10 helix 165-169, Alpha helix 172-192, Alpha helix 194-197, Alpha helix 200-227) and of 2 beta-sheet (129-130 and 160-163).&lt;br /&gt;
The proportion of each structure is 43% of &amp;lt;scene name=&#039;56/568013/Alpha_helix/9&#039;&amp;gt;Alpha Helix&amp;lt;/scene&amp;gt;(7 helix, 62 residues) and 2% of &amp;lt;scene name=&#039;56/568013/Beta_sheet/1&#039;&amp;gt;Beta Sheet&amp;lt;/scene&amp;gt; (2 strands, 4 residues).&lt;br /&gt;
&lt;br /&gt;
3 residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
A lot of empty structures are present between helix.&lt;br /&gt;
One of the structure is called 3/10 helix (Each amino acid corresponds to a 120° turn in the helix).&lt;br /&gt;
&lt;br /&gt;
{{STRUCTURE_3haf|  PDB=3haf  |  SCENE=  }} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Tertiary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Between the Cysteine 179 and the Cysteine 214 we can find a &amp;lt;scene name=&#039;56/568013/B/1&#039;&amp;gt;disulphide bound&amp;lt;/scene&amp;gt; which links helix 2 and the helix 3.&lt;br /&gt;
It exists also a specific loop at R164-S170 residues. This loop aim to stabilize the 129-130 beta-sheet. The R164 is able to make a hydrogen bond with G126, creating a conformational bridge.&lt;br /&gt;
The structure shows moreover a hairpin structure at the N-ter domain.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Quaternary structure==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The protein exists in majority in its dimer form. &lt;br /&gt;
Between each &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Nonpolar_at_dimer_interface/2&#039;&amp;gt; helix 144-156&amp;lt;/scene&amp;gt; of the two proteins, it exists many interactions whose stabilize the dimer interface. It can be retain acidic and mostly negative residues, or basic and positive residues.&lt;br /&gt;
Each  is linked to the C-terminal &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Helix_2_with_helix_3/1&#039;&amp;gt; helix 200-225&amp;lt;/scene&amp;gt; of the other monomer. [http://en.wikipedia.org/wiki/Van_der_Waals_forces Van der Waals] forces are here between such nonpolar residues as valine, isoleucine, and nonpolar sections as histadine, methionine, and glutamic acid.&lt;br /&gt;
It occurs  hydrogen bonding between the dimers at &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Interface_hydrogen_bonding/1&#039;&amp;gt;Thr188 O−Gly195 N&amp;lt;/scene&amp;gt;, Thr190 O−Lys194 N and Thr192 O−Thr192 N&lt;br /&gt;
On each monomer, a Hydrogen bond between &amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bond_asp_202/1&#039;&amp;gt; Asp 202 and Thr 199&amp;lt;/scene&amp;gt;  stabilize the dimeric structure.&lt;br /&gt;
&amp;lt;scene name=&#039;User:Erin_May/Sandbox_1/Hydrogen_bonding/1&#039;&amp;gt; Arg 220 and Ser 132&amp;lt;/scene&amp;gt; form a Hydrogen bond located at the end of helix 3 which permit the inter-chain interactions to be specific.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Ligand and interactions =&lt;br /&gt;
&lt;br /&gt;
 [[Image:Ligand cl.jpg|left|200px||thumb|&#039;&#039;&#039;Bond between 3HAF domain and the Ligand Cd2+&#039;&#039;&#039;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are 3 types of &#039;&#039;&#039;non-polymeric&#039;&#039;&#039; entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
&lt;br /&gt;
This domain 3HAF of the human prion can bind &amp;lt;scene name=&#039;56/568013/Ligand/1&#039;&amp;gt;Ligand&amp;lt;/scene&amp;gt;(copper (II) ions) with high affinity: &#039;&#039;&#039;Cd2+&#039;&#039;&#039; [http://en.wikipedia.org/wiki/Cadmium cadnium ions] and &#039;&#039;&#039;Cl-&#039;&#039;&#039; (chloride ion). Moreover, the entire protein can bind a Cu2+ ions on this NH2 tail and this bond can induce &#039;&#039;&#039;conformational change&#039;&#039;&#039; with a lot of unknown effect. 3 others residues can have a contact with metals; S132, H140 and D147.&lt;br /&gt;
In fact, the 3haf domain is only one chain with 2 binding sites for residues CD (H40 and D147)and 1 binding domains for CL S132.&lt;br /&gt;
&lt;br /&gt;
The entire 3HAF domain can interact with [http://en.wikipedia.org/wiki/GRB2 Growth factor receptor-bound protein 2] (GRB2), [http://en.wikipedia.org/wiki/Exoribonuclease exoribonuclease 3](ERI3) and [http://en.wikipedia.org/wiki/Synapsin_I Synapsin I] (SYN1). There are 3 types of non-polymeric entities that can bind this domain:cadmium ion, chloride ion, water.&lt;br /&gt;
For this domain, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
= Repercussion of the M129/V129 polymorphism =&lt;br /&gt;
&lt;br /&gt;
[[Image:C:\Users\Pierre-Yves\Desktop\images.jpg]]&lt;br /&gt;
&lt;br /&gt;
It’s known that the transformation of the normal protein in its infectious model involves a conversion from a soluble and predominantly α-helical protein to an aggregated form, which is substantially enriched in β-sheet.&lt;br /&gt;
&lt;br /&gt;
The substitution by a valine at residue 129 influences intermolecular beta-sheet formation and conformation. Even if the structure is not distorted by the substitution (no effect on the stability, folding, or dynamics), the difference is based on the interaction by the beta-sheet between two dimers. With two M129 dimers, there is an identical and stable intermolecular 129-130 beta-sheet interaction. However with two V129 variant dimers, it appears a flexion, form to prevent steric troubles between them. In some cases of variants, the beta-sheet interface is entirely absent. This tendency allows [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808380/figure/f3/ the exposure of beta-sheet to the exterior of the protein] and thus occasionally influences the aggregation form and so the development of prions.&lt;br /&gt;
&lt;br /&gt;
The common Methionine/Valine polymorphism residue in 129 in the PrP influences disease.&lt;br /&gt;
For example,valine 129 is finding on CJD whereas methionine 129 is find in FFI.&lt;br /&gt;
&lt;br /&gt;
A lot of others mutations can be finding in these diseases: for example, a substitution of Arginine 208 in  Histidine 208 can hae an effect on mental disease and is finding in CJD. At the same way, a subtitution of Asparagine 171 in Serine 171 can be finding in schizoaffective disorder.&lt;br /&gt;
&lt;br /&gt;
For this 3HAF, two glycosylated sites exist on helix 2 and 3 at Asn181 and Asn197. A [http://en.wikipedia.org/wiki/Disulfide_bond disulfide bond] exist between Cys179 (helix 2) and Cys214 (helix 3).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=See Also=&lt;br /&gt;
*[[Prion|Prion]]&lt;br /&gt;
*[http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=3haf&amp;amp;template=main.html PDBSum]&lt;br /&gt;
*[http://www.ebi.ac.uk/pdbe-srv/view/entry/3haf/summary.html EMBISum]&lt;br /&gt;
&lt;br /&gt;
=Reference=&lt;br /&gt;
&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:019927125&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category: Homo sapiens]]&lt;br /&gt;
[[Category: Antony, L.]]&lt;br /&gt;
[[Category: Hartmann, R.]]&lt;br /&gt;
[[Category: Knaus, K J.]]&lt;br /&gt;
[[Category: Lee, S.]]&lt;br /&gt;
[[Category: Surewicz, K.]]&lt;br /&gt;
[[Category: Surewicz, W K.]]&lt;br /&gt;
[[Category: Yee, V C.]]&lt;br /&gt;
[[Category: Cell membrane]]&lt;br /&gt;
[[Category: Disease mutation]]&lt;br /&gt;
[[Category: Disulfide bond]]&lt;br /&gt;
[[Category: Glycoprotein]]&lt;br /&gt;
[[Category: Golgi apparatus]]&lt;br /&gt;
[[Category: Gpi-anchor]]&lt;br /&gt;
[[Category: Lipoprotein]]&lt;br /&gt;
[[Category: Membrane]]&lt;br /&gt;
[[Category: Membrane protein]]&lt;br /&gt;
[[Category: Prion]]&lt;/div&gt;</summary>
		<author><name>Pierre-Yves Mocaer</name></author>
	</entry>
</feed>